Simmons First National Corp: 1 director

A director at Simmons First National Corp sold/sold after exercising options 15,625 shares at 17.230USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...

Miss on earnings due to MedTech

TKH GROUP NV : Preview Q1 2024: In line with guidance

>Not a great start of the year but in line with guidance - TKH will publish Q1 2024 results on May 6. An analyst call is scheduled for 10h CET. Although we do not have a quarterly model per business unit, we do try to forecast Q1 and Q3 based upon our detailed H1 and H2 forecasts. We forecast sales of €429m (Q1 2023 €473m or €441m restated for the divestment of TKH France) and organic growth of -2.5% (Q1 2023 +8.1%). This is driven by Smart Vision (still modest desto...

Orège : A deterioration in 2023 results – 2024 should be another trans...

>Sales of € 1.2m, down 64%, underlying operating profit of -€ 7.8m - Orège reported on Tuesday its 2023 earnings that fell short of our forecast. For sales at € 1.2m down 64%, underlying operating profit stood at -€ 7.8m and attributable net profit came to -€ 10.2m. At 31 December 2023, group net debt stood at € 45.2m (debt at € 45.8m of which € 45m is related to advances on the shareholder current account and the cash position of € 0.6m). Since end-2023, a new advan...

Metrovacesa : Q1 2024 results: Solid figures on track for their target...

>On track to meet its FY targets - Metrovacesa posted Q1 2024 results broadly in line with our expectations and its FY guidance. From the quarterly results of the company, we highlight the following:Deliveries stood at 364 units (+10% YoY) to generate €140m in revenues during the first quarter upon a higher ASP per unit of €375k due to product mix. We expect company to remain below the 2,000 units to be delivered in 2024. Residential development margin impr...

Churchill Downs Inc: 1 director

A director at Churchill Downs Inc bought 3,800 shares at 130.220USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Worldline : Début d’année apportant du crédit aux objectifs 2024

>Croissance organique faible au T1 mais au-dessus des attentes - Worldline vient de publier son CA au titre du T1 2024. Il fait ressortir une croissance organique faible à +2.5% mais au-dessus des attentes (ODDO BHF / consensus = +1.2/+0.7%) et en amélioration par rapport au point bas du T4 2023 (+1.3%).Les Services aux Commerçants s’avèrent plus dynamique que prévu (+3.9% dont +6.5% hors arrêt planifié de commerçants – rappel T4 2023 = +3.2%) grâce à de bons rés...

WOOD Flash - Air Astana Group: 1Q24 – 15% ASK growth, RASK down slight...

Air Astana Group’s 1Q24 revenue and EBITDAR were broadly in line with our expectations. During the seasonally-weakest quarter of the year, the RASK was slightly (4%) lower yoy. This was driven by a combination of: 1) the high base effect (with 1Q23 boosted by people fleeing the military draft in Russia, to and via Kazakhstan); and 2) a growing share of FlyArystan in the revenue mix. Both of these factors were flagged by the company along with the 4Q23 results. If adjusted for the positive one-of...

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

Higher guidance, 15% beat on Q1 EBIT

GALP : Résultats T1 supérieurs aux attentes, outlook rassurant. Recomm...

>Upstream : un profil de croissance solide renforcé par les découvertes en Namibie - L’EBITDA T1 2024 ajusté de l’Upstream est ressorti à 591 M€ et 9% au-dessus des attentes. Le groupe guide sur un EBITDA 2024 de la division à 2.1 Md€ qui nous parait assez conservateur et une production >115 kbep/j en ligne avec nos attentes. Cette production devrait croitre de de plus de 30% (+40 kbep/j) avec le démarrage de Bacalhau au Brésil fin 2025 qui devrait atteindre son pl...

Mercedes-Benz AG : Continued erosion and risks still underestimated

>Continued erosion of Cars fundamentals - MBG reported subdued Q1 results Tuesday morning, below expectations (adjusted EBIT 5% below consensus, -10% for the Cars division), see First Take. The group reported a marked erosion of its earnings and margins in the Cars division (adjusted EBIT € 2.3bn, -44% y-o-y, margin 9.0%, -580bp y-o-y), partly offset by a still very solid performance from Vans (adjusted EBIT € 0.8bn, +11% y-o-y, margin 16.3%, -20bp y-o-y). The group ...

GSK : Very good start to the year

>Q1 beat expectations - GSK reported Q1 sales (+4.4% vs consensus) and core EPS (+15.9% vs consensus) ahead of expectations. Sales were up 10% at cc (+6% GBP). All divisions turned in a good performance: Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs consensus) driven by Arexvy (£ 180m - launched in Q3 2023, in line) and Shingrix (+13.4%, +4.4% vs consensus) General Medicine declined less sharply than expected (-4.4%, +7.7% vs consensus). Core EB...